title: Development of prenatal screening--A historical overview.
abstract: The first prenatal screening test to be introduced was based on a single maternal serum marker of neural tube defects. Since then various prenatal screening concepts have been developed, the most successful being Down syndrome risk estimation using multiple serum and ultrasound markers. Today a completely new approach to aneuploidy screening is available based on maternal plasma cell-free DNA testing. This has the potential to markedly improve screening performance but routine testing is currently too expensive in a public health setting. However, it can be cost-effective when used in combination with existing multi-maker tests. Some are beginning to broaden prenatal screening to include pregnancy complications such as pre-eclampsia that can be prevented using soluble low-dose aspirin treatment started before 16 weeks of gestation. Prenatal screening for cardiac abnormalities, fragile X syndrome and recessive genetic disorders is underutilized and public health planners should considered a more widespread application of available methods.
authors.affiliation: Department of Obstetrics and Gynecology, Columbia University Medical Center, 662 W 168th St, PH1666, New York, NY 10032-3725. Electronic address: hsc2121@columbia.edu.
authors.forename: Howard
authors.initials: H
authors.lastname: Cuckle
authors.affiliation: Department of Obstetrics and Gynecology, Assaf Harofeh Medical Center, Zerifin, Israel.
authors.forename: Ron
authors.initials: R
authors.lastname: Maymon
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002474:Cell-Free System; D004247:DNA / Q000097:blood*; D004314:Down Syndrome / Q000175:diagnosis; D005260:Female; D005600:Fragile X Syndrome / Q000175:diagnosis; D006330:Heart Defects, Congenital / Q000175:diagnosis; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D009436:Neural Tube Defects / Q000175:diagnosis; D011225:Pre-Eclampsia / Q000175:diagnosis / Q000517:prevention & control; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000266:history*; D016216:Ultrasonography, Prenatal / Q000266:history*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D004247:DNA; D001241:Aspirin
keywords: Down syndrome; Fragile X syndrome; Markers; Pre-eclampsia; Prenatal screening; Spina bifida